Target intelligence / Profile preview

Gut-skin axis (GSA)

Target
GSA
Molecular classification
Other
01

Overview

The gut-skin axis refers to the bidirectional communication pathway between the gastrointestinal system and the skin, primarily mediated by the gut microbiota, the immune system, and metabolic signaling (Salem et al., 2018). This axis plays a critical role in maintaining skin homeostasis and modulating systemic inflammation (De Pessemier et al., 2021). Disruptions in the gut microbiome, known as dysbiosis, or increased intestinal permeability can lead to the translocation of bacteria and metabolites into the bloodstream, triggering inflammatory responses that manifest as dermatological conditions (O'Neill et al., 2016). Therapeutic strategies targeting this axis often involve the use of probiotics, prebiotics, and dietary modifications to restore microbial balance and improve skin health. While not a single molecular target, the gut-skin axis represents a complex network of interactions involving various receptors and signaling molecules. Understanding this axis is essential for developing holistic treatments for chronic inflammatory skin diseases like psoriasis and atopic dermatitis. Research suggests that gut-derived metabolites like short-chain fatty acids can influence skin cell differentiation and immune profile. Consequently, the modulation of this axis is an emerging area of interest for both pharmaceutical and nutraceutical interventions.

Other names
Gut-skin relationshipIntestinal-cutaneous axisMicrobiome-skin axis
02

Mechanism of action

Modulation of the gut microbiota to influence systemic immune responses and skin health through the production of metabolites like short-chain fatty acids (SCFAs) and the regulation of intestinal permeability (Salem et al., 2018; De Pessemier et al., 2021).

03

Biological functions

Immune responseMetabolic homeostasisNeuroendocrine signalingBarrier function regulation
04

Disease associations

Atopic dermatitisPsoriasisAcne vulgarisRosaceaAlopecia areataVitiligo
05

Safety considerations

Risk of bacteremia in immunocompromised patientsPotential for gut dysbiosis with long-term antibiotic useVariable efficacy due to individual microbiome differences
06

Interacting drugs

Lactobacillus rhamnosus

4 more in the full profile.

07

Biomarkers

Gut microbiome diversityShort-chain fatty acids (SCFAs)ZonulinCalprotectinC-reactive protein (CRP)

Beyond the preview

Go deeper on Gut-skin axis (GSA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut-skin axis (GSA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call